U.s.aRNA-based Vaccine test successful on the person ensures safety, less time as well as production costs.
Since early January 1, after China announced the gene sequence of nCoV, many pharmaceutical companies immediately participated in the race for the vaccine. New trials, handshake between direct opponents, all to find the safe and effective method of preventing Covid-19.
On 18/5, biotech company Moderna said the first vaccine test has the ability to stimulate the immune system to antibody immunity against nCoV, the concentration equal to the person who has cured the disease. If the results are possible, experts expect the first vaccination dose to be present at the end of the year or early 2021.
The Vaccine of Moderna is based on information RNA (genetic material). This is a new technology, which has never been used before. Scientists will synthesize the genetic conductor, carrying the body’s genetic code to the cell manufacturing plant.
The first advantage of vaccine RNA is Safety level.
Often, traditional vaccines contain viruses that have a reduced virality or discontinuation, which is generated through genetic engineering. When injected into the body, they trigger a long-term immune response, which resembles a person who has cured the disease.
Meanwhile, vaccine RNA uses the human cell itself, the “guide” body produces the same ‘ thorny protein ‘ virus. This helps the body to strengthen the likelihood of immune responses, including the reaction of B cells and T. Vaccine RNA is not generated from the pathogen, so it is not possible to cause infection to the user.
The fabrication and production of great tea Also Fast And Consuming Little Cost More.
Stéphane Bancel, CEO of Moderna, said: “You can copy and paste information about the drugs by using the same technology. This is exactly how we prepared the vaccine. “
With only one production process and one instrument line, the company can create various types of vaccines, including vaccine nCoV. The only difference is the gene sequence of the virus. The new method of solving time and cost problems is particularly effective in the urgent context of the epidemic.
Director Bancel said the company started working since January 1, shortly after China shared the virus genome sequence. By January 3, this became the first type of nCoV vaccine to be approved for clinical trials. In a statement, Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases, called this “record Speed”.
A phase trial of 45 adults, healthy between the ages of 18 and 55. Each person is injected two-nose vaccine, separated 28 days, low, moderate to high doses.
The safety data and the level of immunity in stage 1 will become the subject for subsequent steps.
Mordena is actively preparing the second stage study, with the participation of 600 people. To develop the vaccine in an emergency situation, the company is expected to cooperate with the U.S. Food and Drug Administration (FDA) and other non-governmental organizations.
“Our goal is to create data that proves safe and effective vaccine against Covid-19”, the site of Mordena information.
While the water runs to race, many times the experts warn Accelerate the testing and development of vaccines that can create a variety of consequences.
In some cases, distribution of the great tea when not tested thoroughly will cause the community to have more severe illness or occurrence of complications. If deviating, the world may be charged by the wave of objections from supporters of the “anti-vaccination” movement, which is the headache from before the Covid-19 outbreak.
“We put very high expectations on the vaccine, but obviously there are many things to be cautious of,” said Dr. Kathryn Edwards, Vanderbilt University pediatrician.
No expert has said that accelerating product development is too dangerous, but many of the recipients need to ensure strict testing and evaluation.
“As opposed to drugs, vaccinesBe injected for a healthy person. We must be very aware not to harm anyone “, Barry Bloom, professor of Public Health School, Harvard University, said.
However, there are also mixed opinions, given that the major delays in approval or vaccine research when the virus kills thousands of people every day is “immoral”.
“If you are developing cancer therapies, you need to risk a little to save many lives, similarly while in the middle of the epidemic,” said Michael Watson, vaccine expert at Moderna.
Shushan (According to Science Magazine, Biopharma Dive, Moderna)